Companies › TwoStep Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TS-104 Peptide-drug conjugate (PDC) delivering monomethyl auristatin E (MMAE) via integrin-target | ITGA, ITGB | Phase 1 | NSCLC (Non-small Cell Lung Cancer) | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07814248 | TS-104 | Phase 1 | NSCLC (Non-small Cell Lung Cancer) | Oncology | Aug 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.